Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30609876 | 0.72 | ADRB3 (0.41) | ALDH1A1KMT2AADRB3TMEM97HRH3 | |
| SCHEMBL9461194 | 0.72 | JMJD6 (0.44) | ALDH1A1KMT2AMAPTADORA3HTT | |
| SCHEMBL27166849 | 0.72 | CYP2C19 (0.39) | ALDH1A1KMT2AHTTHSD17B10KDM4E | |
| SCHEMBL23883159 | 0.72 | ALDH1A1 (0.47) | ALDH1A1KMT2AGAAKDM4E | |
| SCHEMBL25414591 | 0.72 | NOTUM (0.44) | ALDH1A1KMT2AGAAMAPTHSD17B10 | |
| SCHEMBL29111665 | 0.71 | KMT2A (0.41) | ALDH1A1KMT2AMAPTADORA3HTT | |
| SCHEMBL22040159 | 0.71 | JMJD6 (0.45) | ALDH1A1KMT2AMAPTADORA3HTT | |
| SCHEMBL6855286 | 0.70 | KMT2A (0.40) | ALDH1A1KMT2AMAPTADORA3HTT | |
| SCHEMBL22435356 | 0.69 | KMT2A (0.40) | ALDH1A1KMT2AGAAADORA3KDM4E | |
| SCHEMBL22435357 | 0.69 | SMN1; SMN2 (0.43) | ALDH1A1KMT2AGAAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-113645971-B | Compounds and uses thereof | 福宏治疗公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3917527-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ALDH1A1 2571/4885KMT2A 792/4885GAA 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.